Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients

[1] Michaelson JS(2018)Breast Cancer. Source: Globocan 2018 World Heal Organ 876 2018-2019

[2] Chen LL(2009)How cancer at the primary site and in the lymph nodes contributes to the risk of cancer death Cancer. 115 5095-5107

[3] Silverstein MJ(2018)Interdisciplinary screening, diagnosis, therapy and follow-up of breast cancer. Guideline of the DGGG and the DKG (S3-level, AWMF registry number 032/045OL, December 2017) - part 2 with recommendations for the therapy of primary, recurrent and advanced Br Geburtshilfe Frauenheilkd 78 1056-1088

[4] Mihm MCJ(2014)Magnetic resonance imaging in breast cancer: a literature review and future perspectives World J Clin Oncol 5 61-70

[5] Sober AJ(2011)Ganzkörper-MRT in der präoperativen Diagnostik des Mammakarzinoms – ein Vergleich mit den Staging- methoden in der S 3-Leitlinie whole-body MRI in preoperative diagnostics of breast cancer – a comparison of Fortschritte Röntgenstrahlen 183 1130-1137

[6] Tanabe KK(2016)Comparative performance of 18F-FDG PET/MRI and 18F-FDG PET/CT in detection and characterization of pulmonary lesions in 121 oncologic patients J Nucl Med 57 582-586

[7] Wockel A(2016)Evaluation of the outcome of lung nodules missed on 18F-FDG PET/MRI compared with 18F-FDG PET/CT in patients with known malignancies J Nucl Med 57 15-20

[8] Festl J(2015)[(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results Eur J Nucl Med Mol Imaging 42 56-65

[9] Stuber T(2013)Depiction and characterization of liver lesions in whole body [(1)(8)F]-FDG PET/MRI Eur J Radiol 82 e669-e675

[10] Brust K(2014)Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT J Nucl Med 55 373-378

[1] Michaelson JS(2018)Breast Cancer. Source: Globocan 2018 World Heal Organ 876 2018-2019

[2] Chen LL(2009)How cancer at the primary site and in the lymph nodes contributes to the risk of cancer death Cancer. 115 5095-5107

[3] Silverstein MJ(2018)Interdisciplinary screening, diagnosis, therapy and follow-up of breast cancer. Guideline of the DGGG and the DKG (S3-level, AWMF registry number 032/045OL, December 2017) - part 2 with recommendations for the therapy of primary, recurrent and advanced Br Geburtshilfe Frauenheilkd 78 1056-1088

[4] Mihm MCJ(2014)Magnetic resonance imaging in breast cancer: a literature review and future perspectives World J Clin Oncol 5 61-70

[5] Sober AJ(2011)Ganzkörper-MRT in der präoperativen Diagnostik des Mammakarzinoms – ein Vergleich mit den Staging- methoden in der S 3-Leitlinie whole-body MRI in preoperative diagnostics of breast cancer – a comparison of Fortschritte Röntgenstrahlen 183 1130-1137

[6] Tanabe KK(2016)Comparative performance of 18F-FDG PET/MRI and 18F-FDG PET/CT in detection and characterization of pulmonary lesions in 121 oncologic patients J Nucl Med 57 582-586

[7] Wockel A(2016)Evaluation of the outcome of lung nodules missed on 18F-FDG PET/MRI compared with 18F-FDG PET/CT in patients with known malignancies J Nucl Med 57 15-20

[8] Festl J(2015)[(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results Eur J Nucl Med Mol Imaging 42 56-65

[9] Stuber T(2013)Depiction and characterization of liver lesions in whole body [(1)(8)F]-FDG PET/MRI Eur J Radiol 82 e669-e675

[10] Brust K(2014)Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT J Nucl Med 55 373-378